CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
D-cycloserine +2 moredrug
Likely dose
D-cycloserine 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02082912
NCT02082912Phase 2Completed
CompareCT.gov

NMDA Receptors in Motor Learning in Humans

Emory University·interventional·Posted Mar 10, 2014·Updated Nov 7, 2018

In Brief

A Phase 2 clinical trial evaluating D-cycloserine, Placebo, and 1 other intervention for Stroke. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The purpose of this study is to focus on enhancing upper limb recovery in patients post-stroke by using robotic-assisted therapy in combination with a drug to improve learning new motor skills.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 10, 2014
Enrollment StartJun 1, 2010
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.3 years ago

Interventions

D-cycloserinedrug

D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks

Placeboother

Placebo pill PO twice weekly (Monday and Wednesday) for three weeks

HandMentor Prodevice

The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).